Receive our newsletter – data, insights and analysis delivered to you
December 17, 2012

UK hospital uses Miracor PICSO system to treat acute heart attack

Manchester Royal Infirmary in Manchester, England, has become the first hospital in the UK to use Miracor Medical Systems' Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) system to treat an acute heart attack (STEMI) patient.

By admin-demo

Manchester Royal Infirmary

Manchester Royal Infirmary in Manchester, England, has become the first hospital in the UK to use Miracor Medical Systems’ Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) system to treat an acute heart attack (STEMI) patient.

The hospital leveraged the Miracor system to perform successful PICSO treatment designed to improve myocardial perfusion following primary PCI.

Manchester Royal Infirmary interventional cardiologist Dr Magdi El-Omar said PICSO has the potential to become standard of care in patients presenting with acute STEMI who may benefit from the technology as a complementary procedure following PCI.

"By favorably redistributing blood towards ischemic myocardium, PICSO may limit infarct size and thus reduce adverse outcomes, including heart failure, which occur in up to two in five of these patients despite a successful percutaneous coronary intervention procedure," Dr El-Omar added.

"Clinical use of the PICSO technology in normal care will shorten the learning curve for Miracor and our key opinion leaders, thereby improving outcomes and reduce health care costs long term."

The PICSO system features the Miracor PICSO impulse console and the disposable, single-use Miracor PICSO impulse catheter.

Miracor’s PICSO impulse system is designed to offer a novel approach to reduce myocardial injury and to refresh ischemic myocardium.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

Positive effects on MACE, restenosis rates, and long-term event-free survival were demonstrated in initial clinical results, according to the company.

Miracor CEO Jon Hoem said results obtained by physicians like Dr El-Omar are important to establish the clinical necessity for the PICSO procedure as a requisite complement to PCI in severe heart attack patients.

"Clinical use of the PICSO technology in normal care will shorten the learning curve for Miracor and our key opinion leaders, thereby improving outcomes and reduce health care costs long term," Hoem added.

"In addition to routine use of the PICSO technology, our 40-patient ‘Prepare RAMSES’ is underway and expected to further demonstrate that PICSO considerably amplifies redistribution of blood into the blood-starved myocardium of severe heart attack patients, even after a successful PCI procedure."


Image: Manchester Royal Infirmary used Miracor’s PICSO system for the first time under CE mark in UK to treat an acute heart attack patient. Photo: KGGucwa.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU